DIAGNAMED HLDGS CORP - DGNMF STOCK NEWS

DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced two key corporate actions: First, the company has granted 4.5 million stock options to directors, officers, and consultants at $0.05 per share, with a five-year expiration and quarterly vesting schedule over one year. Second, the board has approved a shares-for-debt settlement of $67,800 through the issuance of 1,356,000 common shares at $0.05 per share to an arm's length creditor.

DiagnaMed Holdings Corp. (OTCQB: DGNMF) has filed a provisional patent application with the U.S. Patent and Trademark Office for novel methods of producing molecular hydrogen to treat neurological and mental health disorders. The patent covers pharmaceutical-based methods and compositions targeting conditions like Dementia, Parkinson's disease, Depression, and Anxiety. The company plans to partner with research institutions and life sciences companies for manufacturing and clinical research, with the product expected to be ready by December 2024. The global hydrogen generation market was valued at $170.14 billion in 2023, with a projected CAGR of 9.3% through 2030. Over 2,000 scientific publications support molecular hydrogen's therapeutic potential, highlighting its antioxidant and neuroprotective properties.

DiagnaMed Holdings Corp. (CSE: DMED, OTCQB: DGNMF) announces its strategic initiative in advancing molecular hydrogen therapies for brain health. The global hydrogen generation market, valued at USD 170.14 billion in 2023, is projected to grow at a 9.3% CAGR from 2024 to 2030. Over 2,000 scientific publications and 100+ human studies support molecular hydrogen's therapeutic potential, demonstrating antioxidant, anti-inflammatory, and neuroprotective effects. The company plans to develop and commercialize novel molecular hydrogen therapies for neurological disorders, offering various doses and administration methods. DiagnaMed aims to partner with companies exploring 'white' hydrogen sources and license technologies from academic institutions.

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is expanding its BRAIN AGE® Brain Health AI Platform to create a potential drug discovery and clinical research AI platform. The company is leveraging EEG data from previous and future research studies to accelerate clinical trial development and discover novel treatments for neurological, psychiatric, and infectious diseases.

BRAIN AGE® estimates brain age by analyzing brain-wave activity and can assess if a brain is aging atypically or if a person is in the early stage of cognitive decline. The platform has been clinically validated in a peer-reviewed paper published in Frontiers in Neuroergonomics, demonstrating its potential for large-scale screening and brain optimization.

The expanded platform aims to accelerate patient recruitment for clinical trials, enhance data analysis, and support drug development decisions. It can also help individuals seek personalized diagnostics and interventions to potentially decrease cognitive decline.

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is offering its BRAIN AGE® Brain Health AI Platform to investigate the impact of weight loss drugs, like Semaglutide, on brain function. This comes after a study showed Semaglutide doesn't negatively impact brain health and is associated with lower cognitive problems and less nicotine dependence.

The global market for obesity drugs is expected to reach $105 billion by 2030. BRAIN AGE® aims to identify potential brain health issues and gain insights into brain function while taking weight loss drugs. The platform uses a low-cost EEG headset and machine learning to estimate brain age and assess cognitive health.

Clinical validation of BRAIN AGE® has shown promising results in screening for age-related vulnerabilities and assessing the risk of developing Alzheimer's disease and other neurological issues.

DiagnaMed Holdings Corp. (CSE: DMED, OTCQB: DGNMF), a healthcare technology company specializing in brain health via AI, has canceled its previously announced private placement offering from May 15, 2024. The cancellation aligns with the company's evaluation of strategic initiatives related to its BRAIN AGE® Brain Health AI Platform. Further updates are anticipated within this quarter.

DiagnaMed Holdings Corp., a healthcare technology firm focused on brain health using AI, has announced a private placement offering of up to $650,000. This offering, led by EMD Financial, is priced at $0.04 per unit. Each unit consists of one common share and one warrant, allowing acquisition of an additional share at $0.05 within 36 months. The proceeds will fund the BRAIN AGE® Brain Health AI Platform and general purposes. The offering is open to most Canadian provinces and closes around June 10, 2024, pending regulatory approvals.

DiagnaMed Holdings Corp. is set to commercialize its BRAIN AGE® Brain Health AI Platform, an innovative solution that estimates brain age and provides a brain health score.

This platform aims to target the global digital brain health market, projected to reach USD 405.53 billion by 2031. BRAIN AGE® assesses brain health using a low-cost EEG headset and a proprietary machine-learning model, making it accessible and affordable for large-scale use.

The platform is clinically validated through studies at Drexel University and the University of Miami, showing its potential in detecting cognitive decline and optimizing brain performance.

BRAIN AGE® targets diverse users, including healthy individuals, athletes, and neurodegenerative patients, with potential applications in up to 10,000 North American clinics. The platform's goal is to empower individuals and healthcare professionals to improve brain health through personalized diagnostics and interventions.

DiagnaMed announced a clinical validation milestone for its BRAIN AGE® Brain Health AI Platform with a peer-reviewed paper. The platform offers a unique solution for estimating brain age and providing a brain health score, as detailed in a publication in Frontiers in Neuroergonomics. This achievement marks a important step for the company in bringing its innovative AI solution to a wider audience, with the CEO highlighting the potential impact on brain health improvement for millions of users.